Understand the source comparison
Hexarelin Safety Profile: Clinical Evidence Comparison
The following table compares hexarelin to other commonly researched growth hormone secretagogues across key safety and efficacy parameters. This structured comparison clarifies where hexarelin's risk-benefit profile diverges from alternatives and guides protoc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares hexarelin to other commonly researched growth hormone secretagogues across key safety and efficacy parameters. This structured comparison clarifies where hexarelin's risk-benefit profile diverges from alternatives and guides protocol design decisions.
- GH Pulse Amplitude
- Very high (8–12x baseline)
- Moderate (3–5x baseline)
- High (6–9x baseline)
- High (6–10x baseline)
- Moderate (sustained elevation)
- Hexarelin produces the strongest acute GH spike but desensitizes fastest
- Cortisol Elevation
- Significant (+35–50%)
- Minimal (<10%)
- Moderate (+20–30%)
- Moderate (+20–35%)
- None
- Cortisol response is dose-dependent and limits chronic hexarelin use
- Prolactin Response
- Moderate (+40–60%)
- Mild (+10–20%)
- Mild (+15–25%)
- Hexarelin's prolactin elevation requires monitoring in male subjects
- Receptor Desensitization
- Rapid (4–8 weeks)
- Minimal (12+ weeks)
- Moderate (8–12 weeks)
- Minimal (sustained)
- Hexarelin requires cycling; continuous use beyond 8 weeks loses efficacy
- Optimal Dosing Frequency
- Once daily (morning)
- 2–3x daily
- Once daily (bedtime)
- Hexarelin's long receptor occupancy makes multiple daily doses counterproductive
- Appetite Stimulation
- Mild
- Moderate
- Strong
- GHRP-6 is the strongest appetite stimulant; hexarelin shows minimal effect
- Cycle Duration Recommendation
- 4–6 weeks on, 2 weeks off
- 12–16 weeks continuous
- 8–12 weeks on, 2 weeks off
- Hexarelin's short cycle requirement limits its use in longer research protocols